Inspiratory Muscle Training in Patients Receiving Allogenic Stem Cell Transplantation

Effectiveness of an Inspiratory Muscle Training in Patients Receiving Allogenic Stem Cell Transplantation

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01281410

Enrollment

106

Registered

2011-01-24

Start date

2011-01-31

Completion date

2013-02-28

Last updated

2011-07-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inspiratory Muscle Training, Respiratory Muscle Training, Stem Cell Transplantation

Keywords

respiratory muscles, hematopoetic stem cell transplantation, inspiratory muscle training

Brief summary

The study is a monocentric, controlled randomized trial. Its an interventional method study. There is a control and an interventional group. The interventional group is receiving a specific inspiratory muscle training with Respifit (special device for inspiratory muscle training) during the first 30 days after allogenic stem cell transplantation. The investigators want to show that the training group gets stronger inspiratory muscles. The investigators measure the change of PIMAX values and MVV values.

Interventions

PROCEDUREInspiratory Muscle Training

Inspiratory Muscle Training with Respifit (5 times per week)

OTHERinspiratory muscle training

Inspiratory muscle training with a device named Respifit for patients receiving a hematopoetic stem cell transplantation (till 30 days after their transplantation)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

17 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Patients receiving allogenic stem cell transplantation * Age 17 - 80 years old * Informed consent

Exclusion criteria

* Actual pneumonia at the beginning of the trial * Impaired vision * Patient is not able to handle Respifit

Design outcomes

Primary

Measure	Time frame	Description
Change of PI max-value from baseline at 30 days after stem cell transplantation	baseline and 30 days after stem cell transplantation	max strength of the inspiratory muscles
Change of MVV-value from baseline at 30 days after transplantation	baseline and 30 days after stem cell transplantation	max voluntary volume for Inspiratory muscle endurance

Secondary

Measure	Time frame
inpatient days	from baseline to maximal 60 days after stem cell transplantation
Incidence of pneumonia	from baseline to 30 days after stem cell transplantation

Countries

Austria

Contacts

Primary ContactHanns Hauser, MD

hanns.hauser@elisabethinen.or.at+43732 7676

Backup ContactUrsula Raschhofer, MSc

ursula.raschhofer@elisabethinen.or.at+437327676

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026